{"id":"NCT02544750","sponsor":"Jazz Pharmaceuticals","briefTitle":"An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)","officialTitle":"A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-31","primaryCompletion":"2021-06-11","completion":"2021-06-11","firstPosted":"2015-09-09","resultsPosted":"2022-07-14","lastUpdate":"2022-07-14"},"enrollment":199,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Tuberous Sclerosis Complex","Seizures"],"interventions":[{"type":"DRUG","name":"GWP42003-P","otherNames":["Cannabidiol","CBD"]}],"arms":[{"label":"GWP42003-P","type":"EXPERIMENTAL"}],"summary":"This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P. However, investigators may subsequently decrease or increase the participant's dose until the optimal dose is found.","primaryOutcome":{"measure":"Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE)","timeFrame":"OLE Day 1 up to 4 years","effectByArm":[{"arm":"GWP42003-P (Double-blind Phase)","deltaMin":117,"sd":null},{"arm":"Placebo (Double-blind Phase)","deltaMin":75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["33346789","34957550"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":124},"commonTop":["Diarrhoea","Seizure","Pyrexia","Decreased appetite","Vomiting"]}}